[
Abstract]
[
Full Text PDF] （in Japanese / 1539KB）
[Members Only And Two Factor Auth.] J.Jpn. Surg. Soc.. 79(9): 1099-1104, 1978
Report on the annual meeting
STUDIES ON PROTRACTED ORAL CHEMOTHERAPY WITH FLUORINATED PYRIMIDINES AS AN ADJUVANT TO SURGICAL TREATMENT FOR STOMACH CANCER, WITH SPECIAL REFERENCE TO CANCER CHEMOTHERAPY BY HEPATIC MICROSOMAL ENZYME INDUCTION
Studies of cancer chemotherapy with FT-207, which was induced by hepatic microsomal enzyme Cytochrome P-450, as an adjuvant to surgical treatment of stomach cancer have been performed since April in 1977. It was studied on 61 patients with curative stomach cancer. These patients were divided into 2 groups, group A with plain chemotherapy, received only 12 to 16 mg/kg/day of FT-207 and group B with intensified chemotherapy by FT-207 combined with phenobarbital and glutathion, an inducer of hepatic microsomal enzyme P-450. Plasma 5-FU levels of group B were compared with those of group A as control. A significant higher level of plasma 5-FU was observed in group B as compared to group A. On the other hand, pharmacokinetic studies of fluorinated pyrimidines have been performed on phenobarbital-treated mice and suggest that the degradation of FT-207 or FD-1, a derivative of FT- 2 07 and a chemical name of 1, 3-bis(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione, by Cytochrome P-450 will be producing metabolic intermediates of more complex structure as compared to 5-FU. The present authors suggest that the longer antitumor effects of FT-207 or FD-1 are due much to the presence of these intermediates. Because of the limited fundamental study and the limited number of patients treated, the drawing of reliable conclusions must await the results of further studies.
To read the PDF file you will need Adobe Reader installed on your computer.